Skip to main content
OpenTrials
Not Yet Recruiting

NCT Number: NCT07010952

AI-based Echocardiographic Quantification in Heart Failure

Heart failure (HF) is a clinical complication. About half of HF patients have heart failure with normal systolic fraction (HFpEF), and most of them are elderly women. The other type is systolic heart failure, characterized by a left ventricular ejection fraction of less than 40 (LVEF<40). The clinical symptoms of HFpEF are very similar to those of low systolic fraction heart failure (HFrEF) with abnormal left ventricular ejection fraction. Generally speaking, the morbidity and severity of HFrEF are higher, and the survival rate is lower. HFpEF is generally difficult to diagnose, so it is critical to find a method to accurately diagnose HFpEF. HFpEF is most commonly diagnosed by echocardiography and biomarkers. In a cardiac ultrasound examination, it is impossible to diagnose HFpEF based on a single parameter of the results. We need multiple examination parameters to gather enough evidence to confirm the existence of HFpEF. These parameters include the mitral inflow velocity pattern, the pulmonary vein flow pattern, changes in flow velocity from the left atrium to the left ventricle, tissue Doppler measurements, and M-mode ultrasound measurements. We train artificial intelligence to distinguish between normal and abnormal cardiac ultrasound images, measure or evaluate all the above parameters, and analyze all the data. We hope that, with the help of artificial intelligence, we can improve the prediction and diagnosis rate of HFpEF.

Simply diagnosing HFrEF requires an LVEF of less than 40%. Diagnosing HFpEF poses significant clinical challenges because no single tool or method can reliably confirm the condition or predict associated hospitalizations. Consequently, diagnosis depends heavily on physician judgment, requiring the synthesis of considerable clinical data and information. Recognizing the heterogeneity of the HFpEF phenotype, phenomapping integrates comprehensive data (clinical history, physiological measurements, biomarkers, ECG, echocardiographic parameters) to stratify patients into distinct subtypes, thereby optimizing classification for improved prognostic prediction. It can be seen from this that HF will rely heavily on artificial intelligence in the future to assist in patient data management and classification diagnosis and further develop clinical prediction models. This research project will implement a multi-center design to collect ultrasound images from patients with heart failure and perform relevant analyses using artificial intelligence.

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age ≥ 18 years.
  • Admission for acute or chronic heart failure between January 1, 2017, and April 30, 2024.
  • Transthoracic echocardiography completed ≤ 48 h after admission with diagnostic-quality DICOM cine loops (parasternal long/short axis and apical 2-/3-/4-chamber views plus Doppler and tissue Doppler).
  • Meets one of the two predefined phenotypes:
  • HFpEF: LVEF ≥ 50 % + typical HF signs/symptoms + objective diastolic dysfunction.
  • HFrEF: LVEF < 40 % in keeping with guideline-defined systolic HF.

Exclusion criteria

  • Mid-range LVEF 40-49 %.
  • Significant native or prosthetic valvular heart disease (moderate-to-severe) requiring surgery or trans-catheter therapy.
  • Congenital heart disease, hypertrophic cardiomyopathy, restrictive or constrictive pericardial pathology, or prior cardiac transplantation/LVAD.
  • Inadequate echocardiographic image quality (e.g., missing views, severe acoustic shadowing) precludes automated analysis.
  • Hemodynamic instability preventing standardized imaging or data collection.
  • Pregnancy.
  • Concurrent enrollment in another interventional trial that may confound results of imaging or biomarkers.

Treatment and study plan

AI-based image analysis

Diagnostic Test

AI-based imaging analysis

AI-based imaging analysis

Other

AI-based imaging analysis

Primary outcomes

  1. AI-driven HF phenotyping

    Time frame: Data analysis period: June 1 to December 1, 2025

    AI-driven HF phenotyping

Sponsors and collaborators

Lead sponsor

Mackay Memorial Hospital

Other

Registry information

Official study title

Artificial Intelligence-based Automatic Echocardiographic Quantification in Advanced Heart Failure (AIED Study)

Important dates

Study start
2025
Primary completion
2025
Study completion
2025
First posted
Jun 8, 2025
Registry last updated
Jun 15, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.